In the last decade, positron emission tomography/computed tomography (PET/CT) with prostate-specific membrane antigen (PSMA) has become the preferred diagnostic test of choice for restaging patients with biochemical recurrence (BR) of prostate cancer (PCa) ((Trabulsi et al. 2020). The gene discussed is FOLH1; the disease is Familial prostate cancer.